Replimune Group Inc — キャッシュフロー (NASDAQ:REPL) | MetaTrader

チャート全体を表示

Financials

概要明細書統計

営業活動によるキャッシュフロー -61.39 M-82.18 M-128.05 M-185.47 M-192.25 M -277.91 M 投資活動によるキャッシュフロー -188.78 M-1.81 M-142.5 M97.2 M-23.8 M 216.64 M 財務活動によるキャッシュフロー 372.46 M6.6 M311.3 M16.28 M252.4 M 10.48 M フリーキャッシュフロー -63.78 M-84.52 M-130.32 M-191.13 M-198.94 M -283.27 M

ニュース

Undercovered Stocks: Zscaler, Aeluma, Devon Energy, And More

U.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.63%

FDA Rejection Sparks Questions On Replimune Drug Approval Path - Replimune Group (NASDAQ:REPL)

原油5％上昇、ファスナルは第1四半期決算を受け下落

Replimune Gets Second FDA CRL for Melanoma Drug BLA, Stock Crashes

ダウが350ポイント以上下落、ゴールドマン好決算も相場支えきれず

Replimune: Second CRL May Have Sealed RP1's Fate - It's Hard To See Positives (REPL)

FDA Review Looms As Replimune Faces Weak Technical Setup - Replimune Group (NASDAQ:REPL)

Iovance Biotherapeutics: Positioned For Multi-Year Growth, Buy The Pullback (NASDAQ:IOVA)

RCKT Stock Down Despite FDA Nod to Gene Therapy in Rare Disease

CORT Rises on FDA Nod to Lifyorli in Platinum-Resistant Ovarian Cancer

Ocugen Falls as Gene Therapy for Eye Disease Lags in Phase II Study